Clinical Trial Update: Trial of PDE4 Inhibition With Roflumilast for the Management of Atopic Dermatitis (Integument-PED) [Phase 3]

View source ↗

Summary

A Phase 3 trial evaluating roflumilast, a PDE4 inhibitor, for the management of atopic dermatitis (eczema) has completed and results have been posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Atopic Dermatitis

Drugs mentioned

• Roflumilast (roflumilast)

Snippet

Sponsor: Arcutis Biotherapeutics, Inc. | Conditions: Atopic Dermatitis Eczema | Phase 3 | Status: COMPLETED | Results posted: 2025-12-23